PDF(Pubmed)
Abstract：
Alzheimer\'s disease (AD) is the most common form of dementia. It increases the risk of other serious diseases and causes a huge impact on individuals, families, and socioeconomics. AD is a complex multifactorial disease, and current pharmacological therapies are largely based on the inhibition of enzymes involved in the pathogenesis of AD. Natural enzyme inhibitors are the potential sources for targeting AD treatment and are mainly collected from plants, marine organisms, or microorganisms. In particular, microbial sources have many advantages compared to other sources. While several reviews on AD have been reported, most of these previous reviews focused on presenting and discussing the general theory of AD or overviewing enzyme inhibitors from various sources, such as chemical synthesis, plants, and marine organisms, while only a few reviews regarding microbial sources of enzyme inhibitors against AD are available. Currently, multi-targeted drug investigation is a new trend for the potential treatment of AD. However, there is no review that has comprehensively discussed the various kinds of enzyme inhibitors from the microbial source. This review extensively addresses the above-mentioned aspect and simultaneously updates and provides a more comprehensive view of the enzyme targets involved in the pathogenesis of AD. The emerging trend of using in silico studies to discover drugs concerning AD inhibitors from microorganisms and perspectives for further experimental studies are also covered here.
摘要：
阿尔茨海默病(AD)是最常见的痴呆形式。它增加了其他严重疾病的风险，并对个人造成巨大影响，家庭,和社会经济学。AD是一种复杂的多因素疾病，目前的药物治疗主要基于抑制与AD发病机制有关的酶。天然酶抑制剂是靶向AD治疗的潜在来源，主要来自植物，海洋生物,或微生物。特别是,与其他来源相比，微生物来源具有许多优势。虽然已经报道了一些关于AD的评论，这些以前的评论大多集中在介绍和讨论AD的一般理论或概述各种来源的酶抑制剂，如化学合成，植物,和海洋生物，而关于抗AD酶抑制剂的微生物来源只有很少的评论。目前,多靶向药物研究是AD潜在治疗的新趋势。然而,没有综述从微生物来源全面讨论了各种酶抑制剂。这篇综述广泛地解决了上述方面，同时更新了并提供了有关AD发病机理中涉及的酶靶标的更全面的观点。本文还涵盖了使用计算机研究从微生物中发现有关AD抑制剂的药物的新兴趋势以及进一步实验研究的观点。
